DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/f7e7a7/epigenetics_therap) has announced the addition of the "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma" report to their offering.
Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma. The report provides insights on segments where epigenetic therapies may prove to be useful. The report also details the market potential for the epigenetic therapies, Furthermore, it provides insights into the epigenetic therapeutics R&D pipeline. The report also contains comprehensive profiles of the epigenetic therapies in late-stage clinical development. The report offers insights into the US, the top five markets in Europe and Japan. The report also elucidates the current competitive landscape of the epigenetic therapeutics market.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Epigenetic drugs are the chemical compounds or biologics that cause epigenetic changes resulting in modified molecular protein expressions. These drugs have the potential to trigger or suppress a protein expression process.
Currently, there are four epigenetic drugs in the market, namely Vidaza, Zolinza, Dacogen and Istodax. The sales of these drugs will account for all of the revenues of the epigenetic therapeutics market. The global epigenetic therapeutics market measured in this report comprises the sales of VIdaza, Zolinza, and Dacogen in the top seven markets of the world.
Four Epigenetics Drugs Generated Revenues of $517m in 2009
Vidaza, Dacogen, Zolinza and Istodax are the four currently approved epigenetic drugs in the market. The sales of these drugs amounted to $517m in 2009. Vidaza and Dacogen are approved for the indication Myelodysplastic Syndrome (MDS) and Zolinza and Istodax are approved for the indication Cutaneous T-cell lymphoma (CTCL). Of all the drugs, Vidaza had the largest market share in 2009, followed by Dacogen.
Vidaza and Dacogen Belong to a Class of Drugs called DNA Methyltransferase Inhibitors that Dominate the Epigenetics Market
Vidaza and Dacogen belong to a new class of drugs called DNA Methyltransferase inhibitors. These drugs cause the removal of the methyl group from the cytosine residue in the DNA and cause the repression of tumor genes. Of all the drugs, Vidaza and Dacogen are the most commonly used drugs for the treatment of MDS. They are currently employed by physicians as a second or third line of therapy.
The Epigenetic Therapies are Currently Only Approved for Blood Cancer
Epigenetic drugs are currently approved to treat MDS and CTCL, which are cancers of the blood cells. MDS is a type of blood cancer that affects the stem cells secreted in the bone marrow. CTCL affects the lymphocytes that secrete T-cells. The accumulation of the proliferated T-lymphocytes in the subcutaneous regions causes a rash-like appearance and progresses to become metastasis.
- Annualized market data from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading technology in this space
- Market characterization
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Key Topics Covered:
- Market Characterization: Global Epigenetics Market
- In-Depth Analysis
- Competitive Landscape
- Epigenetic Therapeutics: Appendix
- Merck & Co
- Celgene Corporation
For more information visit http://www.researchandmarkets.com/research/f7e7a7/epigenetics_therap
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: United States Europe Asia Pacific North America Japan
INDUSTRY KEYWORDS: Health Genetics Oncology Pharmaceutical